Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 6)

Link copied
Case Copied 17 min read

FEDERAL COURT OF AUSTRALIA

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 6) [2024] FCA 480

File number: NSD 656 of 2017
Judgment of: NICHOLAS J
Date of judgment: 10 May 2024
Catchwords: PATENTS – appropriate form of declaration of infringement – amendment of claim for additional damages – whether outside terms of leave previously granted – whether costs relating to preparation of written evidence should be reduced – whether such costs unreasonably or unnecessarily incurred  
Legislation:

Federal Court Rules 2011 (Cth) r 40.30

Patents Act 1990 (Cth) ss 13(1), 19(1), 117, 122

Cases cited:

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 4) [2020] FCA 1776

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 22
Date of hearing: 2 May 2024
Counsel for the Applicant/Cross-Respondent: Mr D Shavin KC with Ms M Evetts
Solicitor for the Applicant/Cross-Respondent: DLA Piper Australia
Counsel for the Respondents/Cross-Claimants: Mr N Murray SC
Solicitor for the Respondents/Cross-Claimants: Herbert Smith Freehills

ORDERS

NSD 656 of 2017
BETWEEN:

NEURIM PHARMACEUTICALS (1991) LTD

Applicant

AND:

GENERIC PARTNERS PTY LTD (ACN 132 833 777)

First Respondent

APOTEX PTY LTD (ACN 096 916 148)

Second Respondent

AND BETWEEN:

APOTEX PTY LTD (ACN 096 916 148)

Cross-Claimant

AND:

NEURIM PHARMACEUTICALS (1991) LTD

Cross-Respondent

AND BETWEEN:

GENERIC PARTNERS PTY LTD (ACN 132 833 777)

Cross-Claimant

AND:

NEURIM PHARMACEUTICALS (1991) LTD

Cross-Respondent

ORDER MADE BY:

NICHOLAS J

DATE OF ORDER:

10 MAY 2024

THE COURT DECLARES THAT:

1.The respondents, acting in concert and pursuant to a common design, infringed claims 4-7 of Australian Patent No. 2002326114 entitled “Method for treating primary insomnia” (“the Patent”):

(a)Pursuant to s 117(2)(b) of the Patents Act 1990 (Cth) (“the Act”), by the supply of Melotin where the respondents had reason to believe that it would be prescribed by a not insignificant number of psychiatrists as a treatment for primary insomnia where the patient complained of non-restorative (or unrefreshing) sleep; and

(b)Pursuant to s 13(1) of the Act, by authorisation of medical practitioners whom the respondents had reason to believe would use Melotin as a treatment for primary insomnia characterised by non-restorative sleep and to improve the restorative quality of sleep in patients aged 55 and over.

THE COURT ORDERS THAT:

2.The cross-claims be dismissed.

3.There be an inquiry as to the quantum of any damages to which the applicant is entitled pursuant to ss 122(1) and 122(1A) of the Act, or, at the election of the applicant, an account of profits in respect of the supply by the respondents during the term of the Patent of any Generic Partners Products or Apotex Products as defined in [5] and [6] of Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360.

4.The respondents are granted leave to appeal the declaration and orders in paras 1-3 hereof.

5.Any notice of appeal that is…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 480
Decision Date

CaseChat Overview and Summary

Neurim Pharmaceuticals (1991) Ltd brought an action against Generic Partners Pty Ltd, seeking declarations of patent infringement, cross-claims, and relief in relation to additional damages. The matter was before the Federal Court of Australia, where the primary legal issues were whether the plaintiff was entitled to amend its claim to seek additional damages, and whether the costs relating to the preparation of written evidence should be reduced on the basis that they were unreasonably or unnecessarily incurred.

The court held that the plaintiff was permitted to amend its claim for additional damages, as it fell within the scope of the leave previously granted. The court found that the costs incurred for the preparation of written evidence were not unreasonable or unnecessary, and therefore, there was no basis to reduce these costs. The court dismissed the cross-claims and ordered an inquiry into the quantum of any damages to which the plaintiff was entitled. The court granted leave for the respondents to appeal the declaration and orders, and directed that any notice of appeal be filed within 28 days. The court further ordered that the applicant's undertaking to the court be discharged and that the applicant's provision of security for the respondents' costs be released. The court also granted the applicant leave to file and serve its further amended statement of claim, subject to certain deletions.

The final orders of the court included the dismissal of the cross-claims, an inquiry into the quantum of any damages to which the plaintiff was entitled, and an order for the respondents to pay the applicant's costs of the proceeding to date, subject to certain exceptions. The court certified that the validity of claims 1 to 7 of the patent was not successfully questioned in the proceeding.

Orders

Orders of the court

2. The cross-claims be dismissed.

3. There be an inquiry as to the quantum of any damages to which the applicant is entitled pursuant to ss 122(1) and 122(1A) of the Act, or, at the election of the applicant, an account of profits in respect of the supply by the respondents during the term of the Patent of any Generic Partners Products or Apotex Products as defined in [5] and [6] of Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360.

4. The respondents are granted leave to appeal the declaration and orders in paras 1-3 hereof.

5. Any notice of appeal that is to be filed pursuant to order 4 hereof be filed and served within 28 days.

6. Order 3 be stayed until the later of:

(a) 28 days from the date of these orders; or

(b) if a notice of appeal is filed within 28 days, until the final determination of any appeal (including any application for special leave to appeal to the High Court of Australia).

7. If no notice of appeal is filed within 28 days from the date of these orders, there be a further directions hearing in relation to the matters referred to in order 3 of these orders on a date to be fixed.

8. The applicant’s undertaking to the Court given on 9 May 2017, and noted in paragraph 4 of the Orders dated 18 July 2017, be discharged.

9. The applicant’s provision of security for the respondents’ costs of and incidental to these proceedings and the respondents’ damages pursuant to the applicant’s undertaking to the Court be released.

10. The applicant be granted leave to file and serve its Further Amended Statement of Claim including para 45A subject to the deletions referred to in [14] of the reasons published today being made.

11. The respondents pay the applicant’s costs of the proceeding (including the costs of the cross-claims and any costs reserved) to date save for:

(a) the costs reserved on 11 December 2020 which are to be determined at the same time as the applicant’s claim for pecuniary relief is determined; and

(b) the costs of the hearing on 2 May 2024 as to which there will be no order as to costs.

AND THE COURT CERTIFIES:

12. Pursuant to s 19(1) of the Act, the validity of each of claims 1 to 7 of the Patent was questioned unsuccessfully in this proceeding.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established